World's Best Scientists 2026 revealed!
Award Badge
Medicine
Poland
2026

D-Index & Metrics

Medicine

D-Index
101
Citations
110355
World Ranking
7770
National Ranking
10

Andrzej Budaj publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrzej Budaj sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 320 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrzej Budaj D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrzej Budaj sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Poland Leader Award
  • 2025 - Research.com Medicine in Poland Leader Award
  • 2023 - Research.com Medicine in Poland Leader Award
  • 2022 - Research.com Medicine in Poland Leader Award

Overview

Andrzej Budaj is affiliated with the Center of Postgraduate Medical Education at Grochowski Hospital in Poland. Their research primarily spans the field of Medicine with a strong focus on Cardiology and Cardiovascular Medicine, complemented by contributions to Surgery, Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism, and Radiology, Nuclear Medicine and Imaging.

The scientist's work covers several important topics including Acute Myocardial Infarction Research, Cardiovascular Function and Risk Factors, Antiplatelet Therapy and Cardiovascular Diseases, Lipoproteins and Cardiovascular Health, Cardiovascular Effects of Exercise, Atrial Fibrillation Management and Outcomes, and Coronary Interventions and Diagnostics.

They have published extensively in frequent venues such as the European Heart Journal, Circulation, Kardiologia Polska, European Heart Journal - Quality of Care and Clinical Outcomes, and the Journal of the American Heart Association.

Frequent coauthors collaborating with Andrzej Budaj include Aldo P. Maggioni, Beata Zaborska, Deepak L. Bhatt, Chris P Gale, and Philippe Gabríel Steg.

Some recent publications of Andrzej Budaj include:

  • 2024 ESC Guidelines for the management of chronic coronary syndromes, 2024, European Heart Journal
  • Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus, 2020, Circulation
  • Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries, 2021, Circulation
  • A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction, 2022, Circulation
  • Comparative Efficacy and Safety of Oral P2Y 12 Inhibitors in Acute Coronary Syndrome, 2020, Circulation

Best Publications

  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

    Salim Yusuf;Steven Hawken;Stephanie Ôunpuu;Tony Dans

  • ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society

    Valentin Fuster;Lars E. Rydén;David S. Cannom;Harry J. Crijns

  • Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

    Lars Wallentin;Richard C. Becker;Andrzej Budaj;Christopher P. Cannon

  • 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

    Gilles Montalescot;Udo Sechtem;Stephan Achenbach;Felicita Andreotti

  • Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

    Alec Vahanian;Helmut Baumgartner;Jeroen Bax;Eric Butchart

  • European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

    Guy De Backer;Ettore Ambrosioni;Knut Borch-Johnsen;Carlos Brotons

  • Apixaban in Patients with Atrial Fibrillation

    Stuart J. Connolly;John Eikelboom;Campbell Joyner;Hans-Christoph Diener

  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

    Marco Valgimigli;Héctor Bueno;Robert A Byrne;Jean-Philippe Collet

  • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

    Lars Rydén;Eberhard Standl;Małgorzata Bartnik;Greet Van den Berghe

  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

    Sanjit S Jolly;Salim Yusuf;John Cairns;Kari Niemelä

  • ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

    R Collins;R Peto;M Flather;S Parish

  • Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

    Marc P. Bonaca;Deepak L. Bhatt;Marc Cohen;Philippe Gabriel Steg

  • A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry

    Kim A Eagle;Michael J Lim;Omar H Dabbous;Karen S Pieper

  • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

    Johannes F. E. Mann;Roland E Schmieder;Matthew McQueen;Leanne Dyal

  • Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.

    Markku S. Nieminen;Silvia G. Priori;Maria Angeles Alonso Garcia;Andrzej Budaj

  • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)

    Valentin Fuster;Lars E. Rydén;David S. Cannom;Harry J. Crijns

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett

  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

    Salim Yusuf;Shamir R. Mehta;Susan Chrolavicius;Rizwan Afzal

  • ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

    Douglas P. Zipes;A. John Camm;Martin Borggrefe;Alfred E. Buxton

  • ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary

    Valentin Fuster;Lars E. Rydén;David S. Cannom;Harry J. Crijns

Frequent Co-Authors

Keith A.A. Fox
Keith A.A. Fox University of Edinburgh
Lars Wallentin
Lars Wallentin Uppsala University
Salim Yusuf
Salim Yusuf McMaster University
Jose Lopez-Sendon
Jose Lopez-Sendon Hospital Universitario La Paz
Shamir R. Mehta
Shamir R. Mehta McMaster University
Christopher B. Granger
Christopher B. Granger Duke University
Alvaro Avezum
Alvaro Avezum Population Health Research Institute
Philippe Gabriel Steg
Philippe Gabriel Steg Université Paris Cité
Joel M. Gore
Joel M. Gore University of Massachusetts Chan Medical School
Shaun G. Goodman
Shaun G. Goodman University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring career options related to medicine in the USA, online nursing degrees provide flexible and affordable pathways. Many students start with nursing programs that allow them to work while completing their education. For those seeking cost-effective options, the rn to bsn online programs are designed for registered nurses who want to advance their qualifications and open doors to new roles in healthcare.

Advancement in nursing can also be achieved through specialized graduate degrees. For example, the affordable online fnp programs are ideal for nurses aiming to become Family Nurse Practitioners, a role in high demand. Those considering the next academic step beyond a Bachelor’s can research the cheapest rn to bsn online options or pursue advanced leadership and research roles with the cheapest dnp programs.

These online pathways offer opportunities for career advancement and skill specialization—all while helping to manage costs and maintain work-life balance. They are especially appealing for those committed to a future in healthcare but seeking alternatives to traditional medical degrees.

Best Scientists Citing Andrzej Budaj

Trending Scientists

Recently Published Articles